Literature DB >> 14991510

Current concepts in SARS treatment.

Takeshi Fujii1, Tetsuya Nakamura, Aikichi Iwamoto.   

Abstract

The outbreak of severe acute respiratory syndrome (SARS) has drawn enormous attention and caused fear worldwide since early 2003. The disease appears to be under control now; however, the possible return of SARS must be emphasized. Although many clinical experiments have been reported, the treatment of SARS is largely anecdotal, and so far no treatment consensus has been reached. We summarize 14 clinical reports and attempt to assess the effectiveness of various treatment regimens. A combination treatment of steroids and ribavirin was widely used empirically from the outset of the epidemic. In general, the use of steroids for SARS seemed beneficial, but the optimal timing, dosage, and duration of treatment have not yet been determined. On the other hand, ribavirin administration apparently reduced neither the rate of intratracheal intubation nor that of mortality. Moreover, significant toxicity, such as hemolytic anemia, has been attributed to ribavirin. A few preliminary trials and in vitro data suggest the possibility of treating SARS with interferon. Other agents, including the HIV protease inhibitor glycyrrhizin and convalescent plasma, remain to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991510      PMCID: PMC7088022          DOI: 10.1007/s10156-003-0296-9

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  22 in total

1.  Altered pathogenesis of porcine respiratory coronavirus in pigs due to immunosuppressive effects of dexamethasone: implications for corticosteroid use in treatment of severe acute respiratory syndrome coronavirus.

Authors:  Kwonil Jung; Konstantin P Alekseev; Xinsheng Zhang; Doo-Sung Cheon; Anastasia N Vlasova; Linda J Saif
Journal:  J Virol       Date:  2007-10-17       Impact factor: 5.103

2.  Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.

Authors:  Mohamad Hesam Shahrajabian; Wenli Sun; Qi Cheng
Journal:  Hum Vaccin Immunother       Date:  2020-08-12       Impact factor: 3.452

3.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  mSystems       Date:  2021-11-02       Impact factor: 6.496

Review 4.  Development of antiviral therapy for severe acute respiratory syndrome.

Authors:  Jindrich Cinatl; Martin Michaelis; Gerold Hoever; Wolfgang Preiser; Hans Wilhelm Doerr
Journal:  Antiviral Res       Date:  2005-04-26       Impact factor: 5.970

5.  Confidence in controlling a SARS outbreak: experiences of public health nurses in managing home quarantine measures in Taiwan.

Authors:  Chih-Cheng Hsu; Ted Chen; Mei Chang; Yu-Kang Chang
Journal:  Am J Infect Control       Date:  2006-05       Impact factor: 2.918

Review 6.  Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome.

Authors:  Charles-Édouard Luyt; Alain Combes; Jean-Louis Trouillet; Ania Nieszkowska; Jean Chastre
Journal:  Presse Med       Date:  2011-11-16       Impact factor: 1.228

Review 7.  Erythropoietin as candidate for supportive treatment of severe COVID-19.

Authors:  Hannelore Ehrenreich; Karin Weissenborn; Martin Begemann; Markus Busch; Eduard Vieta; Kamilla W Miskowiak
Journal:  Mol Med       Date:  2020-06-16       Impact factor: 6.354

8.  Management guidelines for obstetric patients and neonates born to mothers with suspected or probable severe acute respiratory syndrome (SARS).

Authors:  Cynthia Maxwell; Alison McGeer; Kin Fan Young Tai; Mathew Sermer
Journal:  J Obstet Gynaecol Can       Date:  2009-04

9.  Cytokine regulation in SARS coronavirus infection compared to other respiratory virus infections.

Authors:  Tamaki Okabayashi; Hiroaki Kariwa; Shin-ichi Yokota; Shigeo Iki; Tomokazu Indoh; Noriko Yokosawa; Ikuo Takashima; Hiroyuki Tsutsumi; Nobuhiro Fujii
Journal:  J Med Virol       Date:  2006-04       Impact factor: 2.327

10.  Annexin A2 on lung epithelial cell surface is recognized by severe acute respiratory syndrome-associated coronavirus spike domain 2 antibodies.

Authors:  Yi-Ting Fang; Chiou-Feng Lin; Pao-Chi Liao; Yu-Min Kuo; Shuying Wang; Trai-Ming Yeh; Chi-Chang K Shieh; Ih-Jen Su; Huan-Yao Lei; Yee-Shin Lin
Journal:  Mol Immunol       Date:  2009-12-16       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.